Additional drugs under development that target NF-κB pathway components upstream of the IKK complex are TLR antagonists and IRAK4 inhibitors, which are potentially interesting for the treatment of DLBCL and WM with MYD88 mutations. Here, NFKB1 is linked to diffuse large B-cell lymphoma.